Featured Stories

  • Understanding Pulmonary Arterial Hypertension Outcome Measures

    Pulmonary arterial hypertension (PAH) is a rare, life-threatening condition characterized by elevated blood pressure in the arteries which carry blood from the heart to the lungs. The high blood...

    Learn More

  • Calgary-based biotech firm specializes in instructing cells to fight complex diseases

    Imagine a world where a host of diseases and conditions caused by non-beneficial instructions from our DNA could be treated simply by instructing our cells to ignore those signals. That science is...

    Learn More

  • Health Matters: Alberta-developed drug could help prevent long COVID

    Health Matters February 2: Calgary company Resverlogix has developed a drug that could not only stop COVID-19 illness from progressing, it also has potential to prevent chronic symptoms, or long...

    Learn More

  • Calgary Company's COVID Drug Going to Phase Two Trials

    Calgary-based biotech company Resverlogix moves into a phase two clinical trial for an oral treatment Apabetalone for COVID-19. And they are looking for patients to participate in the study....

    Learn More

  • Made-in-Alberta drug being tested on COVID-19 patients

    New drug trial to treat COVID-19 patients has been launched at the University of Alberta. Hiba Kamal-Choufi reports.

    Learn More

  • 'Exciting breakthrough': COVID-19 drug trial to take place in Edmonton

    Trials for a Canadian-developed COVID-19 treatment are set to begin at the University of Alberta. CTV News Edmonton - Aired January 24, 2022

    Learn More

  • An Alberta-developed oral treatment for COVID-19 has begun testing at the University of Alberta hospital

    J'lyn Nye interviews RVX President & CEO Donald McCaffrey about our Phase 2b COVID-19 Clinical Trial on 630 CHED

    Learn More

  • Some COVID-19 patients in Edmonton begin potential trial treatment, apabetalone, an Alberta-developed drug

    By Kellen Taniguchi Edmonton Journal, January 18, 2022  

    Learn More

  • Epigenetic Therapies Start Operating Outside the Lines

    Drug developers are sourcing novel structures, bridging transcriptional and signaling domains, and exploring applications beyond oncology GEN: Genetic Engineering and Biotechnology News...

    Learn More

  • Resverlogix in Active Discussions with Morocco

    Resverlogix is in active discussions for COVID-19 clinical studies in Morocco involving apabetalone.

    Learn More

  • Donald McCaffrey at Benzinga All Access

    Resverlogix President & CEO Donald McCaffrey presents at Benzinga All Access conference 2021

    Learn More

  • Resverlogix: The Future of Drug Development

    Clip of Donald McCaffrey, President & CEO of Resverlogix which aired on Fox News December 18, 2021.   © 2021 www.B-TV.com . All Rights Reserved.  

    Learn More

  • Apabetalone meets primary endpoint in PAH pilot study

    Resverlogix reported that its lead drug apabetalone met its primary endpoint in a pulmonary arterial hypertension or ‘PAH’ investigator led pilot study. Watch the news...

    Learn More

  • EVERSANA & Resverlogix Discuss Partnership On PharmaVOICE Webinar

    Rohit Sood, EVP, COMPLETE Commercialization, EVERSANA / Donald McCaffrey, President & CEO, Resverlogix: Next Generation Commercial Innovation: Moving From Promise to Practice. 

    Learn More

  • Donald McCaffrey featured on Innovators with Jane King

    Donald McCaffrey, President & CEO of Resverlogix featured on Innovators with Jane King. Latest updates on the Company's COVID-19 program.

    Learn More

  • COVID-19 Program Update with Donald McCaffrey

    CEO Donald McCaffrey joined PBA à Noon, for a live webinar and Q&A, to discuss the latest developments in Resverlogix' COVID-19 program.

    Learn More

  • Health Canada Authorizes COVID-19 Clinical Study

    Resverlogix receives "No Objection Letter" from Health Canada, approving the COVID-19 Clinical Trial Application for apabetalone.

    Learn More

  • Apabetalone May Prevent Heart Damage Caused by COVID-19

    COVID-19 affects not only lung and respiratory tissue but can injure your heart as well. One study, published in the Journal of the American Medical Association, found that 78% of recently...

    Learn More

  • Balancing Epigenetics in the Treatment of Chronic Kidney Disease

    Kidneys are the body’s filtration system . They clean our blood, removing waste and helping manage blood pressure by controlling the outflow of water. Unfortunately, when these filters...

    Learn More

  • Targeting Epigenetics as a New Therapy in Vascular Disease and Dementia

    Cardiovascular disease literally means disease of the heart and blood vessels, but it can cause additional life-altering complications that we might not initially associate with the disease,...

    Learn More

  • The Faces of Cardiovascular Disease: Series Final

    This is the final article of the mini-series, The Faces of Cardiovascular Disease , looking at the different presentations, symptoms, and root causes of a disease that affects millions of men...

    Learn More

  • The Faces of Cardiovascular Disease: Part 4

    This article is part of a mini-series, The Faces of Cardiovascular Disease , looking at the different presentations, symptoms, and root causes of a disease that affects millions of men and women...

    Learn More

  • The Faces of Cardiovascular Disease: Part 3

    This article is part of a mini-series, The Faces of Cardiovascular Disease , looking at the different presentations, symptoms, and root causes of a disease that affects millions of men and women...

    Learn More

  • The Faces of Cardiovascular Disease: Part 2

    This article is part of a mini-series, The Faces of Cardiovascular Disease , looking at the different presentations, symptoms, and root causes of a disease that affects millions of men and women...

    Learn More

  • The Faces of Cardiovascular Disease: Part 1

    This article is part of a mini-series we are calling The Faces of Cardiovascular Disease , looking at the different presentations, symptoms, and root causes of a disease that affects millions of...

    Learn More

  • Apabetalone: A Relative Size Animation

    Our lead compound – apabetalone – is the first small molecule of its kind with potentially important benefits for patients with high-risk cardiovascular and other chronic diseases. But...

    Learn More

  • The Faces of Cardiovascular Disease: Part 4

    This article is part of a mini-series, The Faces of Cardiovascular Disease, looking at the different presentations, symptoms, and root causes of a disease that affects millions of men and women around the world. Be sure to read parts 1, 2, and 3 here. In this installment, we explore features of chronic kidney disease, with a focus on vascular calcification. As this series comes to a close, stay tuned for future articles focusing on other areas of Resverlogix’s ongoing research and treatment options.

    We all know the feeling of exhaustion. It’s not just that you’re tired, everything becomes more difficult; it’s harder to get up, harder to get moving, harder to focus, harder to function. You feel drained.

    For most of us, a really good night’s sleep, or a relaxing weekend getaway, is all it takes to rejuvenate our energy levels. However, for people with chronic kidney disease (CKD), fatigue can become a normal part of daily life. What most of us don’t realize is how dramatically constant exhaustion can affect you and those around you.

    The persistent fatigue experienced by people with CKD is difficult for a healthy person to relate to, and often leaves CKD sufferers feeling misunderstood by friends, family and co-workers.

    Just imagine feeling too tired to plan your spouse’s birthday – knowing that they deserve to feel special and appreciated, not feeling able to muster up the energy to attend family gatherings, even during the holidays, or being so exhausted by the end of the day that all you can think about is quitting your job. Then the guilt kicks in, and makes it all feel even worse.

    Fatigue is subjective by nature. There is a stigma around complaining of tiredness. People tend to think you are lazy and unmotivated, and no one wants to be known as the “complainer”. The stigma is so strong that people with CKD will deliberately neglect to mention their fatigue, even to their doctor, and so it is commonly underreported and undertreated. But fatigue’s effects are very real, and it should be taken seriously.

    Fatigue in CKD is caused by a number of disease-related factors: low red blood cell production (renal anemia), build-up of waste and toxins in the blood due to improper filtering by the kidneys, high potassium levels, high blood pressure, and calcification in blood vessels – making it more difficult for the heart to pump blood throughout the body. All of these factors are linked in CKD: they feed each other in a vicious cycle.

    These same issues also contribute to cardiovascular disease (CVD). It’s well known that CKD can cause CVD, and vice versa. One of the primary drivers of CKD and related CVD is an imbalance in calcium and phosphorus levels in the body. This leads to the serious consequence of vascular calcification.

     

    In CKD, the buildup of waste and toxins, which leads to the imbalance in calcium and phosphorus levels in the blood, creates “osteogenic” – or “bone-forming” conditions. Under these conditions, processes normally reserved for bone growth and healing are inappropriately activated in vascular smooth muscle cells, found in the middle layer of blood vessels.

    Once activated, these cells transform from elastic and stretchy into rigid cells that behave like bone. Hard, calcium-rich minerals are deposited inside the blood vessel walls. This process is called vascular calcification.

    Epigenetic changes are responsible for this disease-state transformation. Markers on genes that normally ensure that a vascular smooth muscle cell stays a vascular smooth muscle cell are removed, and markers on genes that drive calcification are added. As the balance shifts so does the cell’s identity – and functionality.

    With stiffening of its transportation highway – vessels and arteries – blood can no longer be easily pumped throughout the body. This is particularly detrimental to the heart. The loss of elasticity in the vessels increases blood pressure and stress on the heart, and can ultimately lead to heart failure. In fact, the extent of vascular calcification in CKD can predict cardiovascular risk.

    Vascular calcification, as described above, is often considered specific to CKD. However, calcification also occurs around atherosclerotic plaques as described in part 2. Together, these and many other factors significantly raise the risk of cardiovascular-related death in people with CKD.

     

    CKD and vascular calcification take decades to develop, and often go unrecognized and undiagnosed until the disease has already destroyed the majority of kidney function. Like with many conditions, prevention and early detection are critical. Knowing the risk factors, staying active, eating well and monitoring your blood pressure are all important steps you can take.

    If you are at risk, make sure you know the warning signs. The kidney foundation of Canada has made a helpful quiz to assess your risk. If you, or someone you know, are feeling chronic and extreme fatigue, see your doctor as soon as possible.

    At Resverlogix, we continue to research the complex biology underlying CKD and associated cardiovascular issues, as well as other multi-factorial diseases. Our goal is to determine how we may be able to help individuals burdened by diseases such as CKD, which have so many complex and intertwined biological underpinnings.

    In the final article of our series, we will discuss the latest developments in the prevention and treatment of cardiovascular disease, and what may be just over the horizon.